<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03556397</url>
  </required_header>
  <id_info>
    <org_study_id>CHIR-01-sentinel</org_study_id>
    <secondary_id>11360/6199/1610/021554</secondary_id>
    <nct_id>NCT03556397</nct_id>
  </id_info>
  <brief_title>Sentinel Lymph Node Biopsy in Patients With Breast Cancer After Neoadjuvant Therapy</brief_title>
  <official_title>Sentinel Lymph Node Biopsy in Patients With Breast Cancer After Neoadjuvant Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Ostrava</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Silesian Hospital in Opava</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Ostrava</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to create clear indications for Sentinel Lymph Node Biopsy (SLNB) or
      Axillary Dissection (AD) in women with breast carcinoma after neoadjuvant therapy by studying
      the false negative rate of SLNB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main object of the study is to evaluate, whether sentinel lymph node biopsy (SLNB) at
      women with breast cancer after neoadjuvant therapy is a method with a high false-negative
      rate. Patients will be classified into groups according to histological findings during SLNB,
      clinical and ultrasonography (USG) findings in the axilla. The aim of this study is to create
      clear indications for SLNB or axillary dissection (AD). In case of extension of SLNB
      indications, there will be a decrease in morbidity after surgical therapy when compared to
      AD, which will mean a profit for the patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The patients will be divided into four groups, according to the stage of the disease prior to neoadjuvant therapy.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No roles in the study will be marked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Clear indications for SLNB or axillary dissection</measure>
    <time_frame>24 months</time_frame>
    <description>Clear indications for SLNB or axillary dissection (AD) in women with breast carcinoma after neoadjuvant therapy using false-negativity rate of SLNB. False-negativity rate of SLNB under 10% is acceptable for avoiding AD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>24 months</time_frame>
    <description>Morbidity after SLNB and AD will be assessed by check-ups provided by clinicians. The result will be the percentage of patients which suffer from some complications after SLNB or AD. Common morbidity rate after AD is 20%, after SLNB 1-2%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>24 months</time_frame>
    <description>Quality of Life will be assessed using the standardised World Health Organisation Quality of Life (WHOQOL) questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>24 months</time_frame>
    <description>The overall survival (in months, years) of the patients will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>24 months</time_frame>
    <description>The disease-free survival (in months, years) of the patients will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>24 months</time_frame>
    <description>The progression-free survival (in months, years) of the patients will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>cN0 before and after neoadjuvant th., SLNB - negative, no AD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with cN0 before and after neoadjuvant therapy, SLNB - negative, without AD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cN0 before and after neoadjuvant th., SLNB - posit., AD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with cN0 before and after neoadjuvant therapy, SLNB - positive, AD (separated histological examination of lymph nodes in levels I and II)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cN1 before neoadj. th., cN0 after neoadj. th., SLNB, AD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with cN1 before neoadjuvant th., cN0 after neoadjuvant therapy, SLNB, AD (separated histological examination of lymph nodes in levels I and II)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cN1 after neoadjuvant therapy, SLNB, AD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with cN1 after neoadjuvant therapy, SLNB, AD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sentinel lymph node biopsy (SLNB)</intervention_name>
    <description>Sentinel lymph node biopsy will be performed in the patients</description>
    <arm_group_label>cN0 before and after neoadjuvant th., SLNB - negative, no AD</arm_group_label>
    <arm_group_label>cN0 before and after neoadjuvant th., SLNB - posit., AD</arm_group_label>
    <arm_group_label>cN1 after neoadjuvant therapy, SLNB, AD</arm_group_label>
    <arm_group_label>cN1 before neoadj. th., cN0 after neoadj. th., SLNB, AD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Axillary dissection</intervention_name>
    <description>Axillary dissection procedure will be performed in the patients</description>
    <arm_group_label>cN0 before and after neoadjuvant th., SLNB - posit., AD</arm_group_label>
    <arm_group_label>cN1 after neoadjuvant therapy, SLNB, AD</arm_group_label>
    <arm_group_label>cN1 before neoadj. th., cN0 after neoadj. th., SLNB, AD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of breast carcinoma confirmed by biopsy

          -  neoadjuvant therapy

          -  examination of axillary lymph nodes clinically and by ultrasound

          -  surgical therapy after neoadjuvant therapy

        Exclusion Criteria:

          -  inflammatory breast carcinoma

          -  incomplete neoadjuvant therapy

          -  previous sentinel lymph node biopsy performed on the same side of the body

          -  disagreement with participation in the study

          -  other malignities influencing the treatment of breast carcinoma

          -  distant metastases
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only women with a history of breast carcinoma will be enrolled in the study.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Žatecký, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Silesian Hospital in Opava</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Petr Vávra, Ass.Prof.,MD,Ph.D.</last_name>
    <phone>0042059737</phone>
    <phone_ext>2544</phone_ext>
    <email>petr.vavra@fno.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiří Hynčica</last_name>
    <phone>0042059737</phone>
    <phone_ext>2587</phone_ext>
    <email>jiri.hyncica@fno.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Silesian Hospital in Opava</name>
      <address>
        <city>Opava</city>
        <state>Moravian-Silesian Region</state>
        <zip>746 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Žatecký, MD</last_name>
      <phone>00420776193203</phone>
      <email>janzatecky.jz@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jan Žatecký, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava-Poruba</city>
        <state>Moravian-Silesian Region</state>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Vávra, Ass.Prof.,MD,Ph.D.</last_name>
      <phone>0042059737</phone>
      <phone_ext>2544</phone_ext>
      <email>petr.vavra@fno.cz</email>
    </contact>
    <contact_backup>
      <last_name>Jiří Hynčica</last_name>
      <phone>0042059737</phone>
      <phone_ext>2587</phone_ext>
      <email>jiri.hyncica@fno.cz</email>
    </contact_backup>
    <investigator>
      <last_name>Otakar Kubala, MD,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiří Prokop, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <reference>
    <citation>Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, Lebeau A, Liedtke C, von Minckwitz G, Nekljudova V, Schmatloch S, Schrenk P, Staebler A, Untch M. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013 Jun;14(7):609-18. doi: 10.1016/S1470-2045(13)70166-9. Epub 2013 May 15.</citation>
    <PMID>23683750</PMID>
  </reference>
  <reference>
    <citation>Caudle AS, Hunt KK, Tucker SL, Hoffman K, Gainer SM, Lucci A, Kuerer HM, Meric-Bernstam F, Shah R, Babiera GV, Sahin AA, Mittendorf EA. American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol. 2012 Oct;19(10):3144-51. doi: 10.1245/s10434-012-2531-z. Epub 2012 Jul 31.</citation>
    <PMID>22847123</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 24, 2018</study_first_submitted>
  <study_first_submitted_qc>June 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2018</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>neoadjuvant therapy</keyword>
  <keyword>sentinel lymph node biopsy</keyword>
  <keyword>axillary dissection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The investigators have not decided to make individual participant data available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

